A Look At Revolution Medicines (RVMD) Valuation After Starting Pivotal Phase 3 RASolute 303 Trial

NodeGuardian · 2026-04-11T16:33:20+00:00

Revolution Medicines has launched its Phase 3 trial for daraxonrasib, boosting stock performance significantly. While the stock appears undervalued, high operating costs and trial risks should be considered by investors.

NodeGuardian

2026-04-11 16:33:20

Abstract generation in progress

Revolution Medicines (RVMD) has initiated its pivotal Phase 3 RASolute 303 trial for its RAS inhibitor daraxonrasib, leading to significant stock momentum with a 216.48% one-year return. Despite trading at $99.12, Simply Wall St’s analysis suggests RVMD is undervalued, with a fair value of $133.70, based on ambitious oncology assumptions. However, this positive outlook is tempered by substantial operating expenses and potential trial setbacks, urging investors to consider both opportunities and risks.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.